Evaluation of neo-adjuvant chemotherapy with different cycles for locally advanced breast cancer
- VernacularTitle:不同周期的新辅助化疗对乳腺癌疗效的影响
- Author:
Fuzhong TONG
;
Bo ZHOU
;
Deqi YANG
;
Yingming CAO
;
Peng LIU
;
Hongjun LIU
;
Shu WANG
;
Xinmin QIAO
;
Jiaqing ZHANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Drug therapy, combination;
Epirubicin;
Paclitaxel
- From:
Chinese Journal of General Surgery
1997;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and toxicity of different cycles of neo-adjuvant chemotherapy for locally advanced breast cancer. Methods Seventy-five patients with locally advanced breast cancer were treated with epirubicin (Epi) plus paclitaxel (TAX, ET regimen). Two cycles were used in 39 patients (2 cycles group) and 4 cycles were used in 36 patients (4 cycles group). Results The overall response rate (RR) was 74% (29/39) in 2 cycles group and 94% (34/36) in 4 cycles group. One patient got clinically complete response (CR), 28 cases had partial response (PR),10 with no change (NC) in 2 cycles group, while 21 patients showed CR including 11 patients with pathologically complete response, 13 with PR, and 2 with NC in 4 cycles group. There was no progression to advanced stage in either groups. Axillary lymph nodes were palpable in all 75 patients before ET regimen, lymph nodes became non-palpable in 46% (18/39) cases in 2 cycles group and in 75% (27/36) cases in 4 cycles group. Toxicities including leukopenia, gastroenteric reactions were similar in the 2 groups, though arthralgia, myalgia, and neurotoxicity were more common in 4 cycles group than 2 cycles group. Conclusion Neo-adjuvant chemotherapy with ET regimen for 4 cycles were more effective than 2 cycles to down staging locally advanced breast cancer. Toxicities including arthralgia, myalgia, and neurotoxicity were more common in 4 cycles group than 2 cycles group.
